PREEMPTIVE THERAPY VS VALGANCICLOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS PREVENTION IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING ALEMTUZUMAB INDUCTION.

2006 ◽  
Vol 82 (Suppl 2) ◽  
pp. 584
Author(s):  
&NA;
Keyword(s):  
Kidney Transplant ◽  
Preemptive Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients

2009 ◽  
Vol 11 (5) ◽  
pp. 400-404 ◽  
Author(s):  
F. López-Medrano ◽  
B. Rueda ◽  
M. Lizasoain ◽  
R. San Juan ◽  
D. Folgueira ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Preemptive Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cytomegalovirus Disease

COMPARISON OF CMV PROPHYLAXIS AND PREEMPTIVE THERAPY IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS.

2000 ◽  
Vol 69 (Supplement) ◽  
pp. S181
Author(s):  
David J. Taber ◽  
Robert E. Dupuis ◽  
Kimberly D. Hollar ◽  
Ann Meehan ◽  
Beverly Rodegast ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Preemptive Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Liver And Kidney ◽  
Cmv Prophylaxis

scholarly journals Coronavirus pneumonia in kidney transplant recipients: current evidence from own clinical experience

2021 ◽  
pp. 129-137
Author(s):  
I. V. Lekareva ◽  
A. L. Emelianova ◽  
E. V. Kalinina ◽  
A. R. Babaeva ◽  
E. V. Scherbinina
Keyword(s):  
Kidney Transplant ◽  
Immunosuppressive Agents ◽  
Adverse Outcomes ◽  
Lung Damage ◽  
Current Evidence ◽  
Preemptive Therapy ◽  
Rapid Progression ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Systemic Complications

The course and management of coronavirus infection (CI) in patients with severe comorbidity are extremely important scientific and practical issues in the era of COVID-19. Kidney transplant recipients make up one of the most vulnerable groups for CI-associated adverse outcomes. Considering the presence of comorbidities, the optimal pharmacotherapy regimens for CI and its complications have not yet been worked out for these patients. In this article, we present two clinical observations demonstrating typical manifestations of coronavirus pneumonia (CP) in kidney transplant recipients, the COVID-19 diagnostic and verification algorithm, and the therapeutic options used to achieve a favorable outcome of CP and to prevent fatal complications. Our findings confirm that in kidney transplant recipients CP is linked to increased disease severity with rapid progression of lung damage and a high risk of developing systemic complications, including thrombotic microangiopathy. It is shown that compliance with the current recommendations for a rational combination of antiviral, anti-inflammatory, anticoagulant and basic immunosuppressive agents in this group of patients provides good treatment outcomes and prevents kidney transplant failure. Two adverse outcomes in the observed group were due to associated opportunistic infection. Based on our findings and clinical data, we conclude that preemptive therapy with IL-6 inhibitors or colchicine is an effective therapeutic option in kidney transplant recipients.

Sign in / Sign up

Export Citation Format

Share Document